Outcome of Innate Pharma’s Annual General Meeting
May 28 2021 - 4:01PM
Outcome of Innate Pharma’s Annual General Meeting
Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq:
IPHA) (“Innate” or the “Company”) announced the voting results of
its shareholders at the Annual General Meeting (“AGM”), which took
place on May 28, 2021, in Marseille, France without the physical
presence of its shareholders. All resolutions were voted on in
accordance with the Executive Board’s recommendations.
A total of 178 votes were cast out of a total of
31,717,812 shares giving right to 32,180,682 voting rights,
representing a quorum of 40.141%.
During the meeting, all seven members of the
Supervisory Board who were up for election were re-elected. Pascale
Boissel’s mandate lasts until the AGM in 2022 and Novo Nordisk A/S,
represented by Marcus Schindler, M.D., decided not to seek
re-election due to Dr. Schindler’s new role as Chief Scientific
Officer of Novo Nordisk A/S. Novo Nordisk A/S remains a shareholder
in the Company but no longer has a seat on its Supervisory
Board.
“Novo Nordisk A/S has been a long-standing
member of Innate’s Supervisory Board, and we thank them for their
valued contributions to the Company,” said Hervé Brailly,
Ph.D., Chairman of the Supervisory Board. “We wish Dr.
Schindler much success in his new role and appreciate his support
of Innate.”
The AGM recording, the resolutions, the results
of the votes and other documents relating to the AGM are available
in the Annual General Meeting 2021 section of the Company’s
website:
https://investors.innate-pharma.com/regulated-information/general-shareholders-meeting
***
The Company’s 2020 20-F is available on the
Investors section of the website.
***
About Innate Pharma:
Innate Pharma S.A. is a global, clinical-stage
oncology-focused biotech company dedicated to improving treatment
and clinical outcomes for patients through therapeutic antibodies
that harness the immune system to fight cancer.
Innate Pharma’s broad pipeline of antibodies
includes several potentially first-in-class clinical and
preclinical candidates in cancers with high unmet medical need.
Innate has been a pioneer in the understanding
of natural killer cell biology and has expanded its expertise in
the tumor microenvironment and tumor-antigens, as well as antibody
engineering. This innovative approach has resulted in a diversified
proprietary portfolio and major alliances with leaders in the
biopharmaceutical industry including Bristol-Myers Squibb, Novo
Nordisk A/S, Sanofi, and a multi-products collaboration with
AstraZeneca.
Headquartered in Marseille, France with a US
office in Rockville, MD, Innate Pharma is listed on Euronext Paris
and Nasdaq in the US.
Learn more about Innate Pharma at
www.innate-pharma.com
Information about Innate Pharma
shares:
ISIN code Ticker code
LEI |
FR0010331421 Euronext: IPH Nasdaq: IPHA 9695002Y8420ZB8HJE29 |
Disclaimer on forward-looking
information and risk factors:
This press release contains certain
forward-looking statements, including those within the meaning of
the Private Securities Litigation Reform Act of 1995. The use of
certain words, including “believe,” “potential,” “expect” and
“will” and similar expressions, is intended to identify
forward-looking statements. Although the company believes its
expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and
uncertainties, which could cause actual results to differ
materially from those anticipated. These risks and uncertainties
include, among other things, the uncertainties inherent in research
and development, including related to safety, progression of and
results from its ongoing and planned clinical trials and
preclinical studies, review and approvals by regulatory authorities
of its product candidates, the Company’s commercialization efforts,
the Company’s continued ability to raise capital to fund its
development and the overall impact of the COVID-19 outbreak on the
global healthcare system as well as the Company’s business,
financial condition and results of operations. For an additional
discussion of risks and uncertainties which could cause the
company's actual results, financial condition, performance or
achievements to differ from those contained in the forward-looking
statements, please refer to the Risk Factors (“Facteurs de Risque")
section of the Universal Registration Document filed with the
French Financial Markets Authority (“AMF”), which is available on
the AMF website http://www.amf-france.org or on Innate Pharma’s
website, and public filings and reports filed with the U.S.
Securities and Exchange Commission (“SEC”), including the Company’s
Annual Report on Form 20-F for the year ended December 31, 2020,
and subsequent filings and reports filed with the AMF or SEC, or
otherwise made public, by the Company.
This press release and the information contained
herein do not constitute an offer to sell or a solicitation of an
offer to buy or subscribe to shares in Innate Pharma in any
country.
For
additional information, please contact: |
Investors Innate Pharma Tel.: +33
(0)4 30 30 30 30 investors@innate-pharma.com |
|
Media Innate Pharma Tracy Rossin
(Global/US) Tel.: +1 240 801 0076 Tracy.Rossin@innate-pharma.com
ATCG Press Marie Puvieux (France) Tel.: +33 (0)9
81 87 46 72 innate-pharma@atcg-partners.com |
Innate Pharma (EU:IPH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Innate Pharma (EU:IPH)
Historical Stock Chart
From Jul 2023 to Jul 2024